

A weak local input can break a strong global model.

Why APAC model inputs demand local evidence validation




THE CHALLENGE

Global models rely on local data integrity.

When APAC market inputs are unvalidated, the downstream impact propagates across pricing models, access strategies, and evidence submissions globally.


Regulatory heterogeneity, fragmented real-world data sources, and inconsistent local methodologies create systemic vulnerability in global pharmaceutical decision architectures.



Evidence fragmentation is not a data problem. It is a strategy problem.

Disconnected evidence generation across APAC markets leads to:

- Inconsistent value narratives across HTA submissions
- Duplicated RWE investments without strategic alignment
- Delayed market access due to evidence gaps
- Weakened global model calibration



Local validation is not a regional task. It is a global imperative.

Organizations that treat local evidence validation as a compliance checkbox rather than a strategic function expose their global models to:

- Systematic bias in health economic assumptions
- Misaligned treatment pathway modelling
- Regulatory rejection risk in key APAC markets
- Erosion of payer confidence in submitted dossiers



Connected evidence architecture enables strategic coherence.

A validated local evidence infrastructure connects:

- Real-world data to global model assumptions
- Local clinical practice to HEOR frameworks
- Regional payer expectations to value narratives
- Market access timelines to evidence readiness



Building validated APAC evidence systems.

- 01** Local Evidence Mapping
Identify gaps between global model assumptions and APAC real-world data availability
- 02** Methodological Alignment
Harmonize local study designs with global HEOR and HTA requirements
- 03** Validation Infrastructure
Build systematic processes for ongoing local input quality assurance
- 04** Strategic Integration
Connect validated local evidence directly into global decision models



How are your APAC model inputs validated against local evidence?

Aurumetrics partners with pharmaceutical organizations to build validated, connected evidence architectures across APAC markets.



aurumetrics.com

The challenge is no longer whether healthcare data exists.

It is whether the right evidence can be generated fast enough?

Yes, it can.

Aurumetrics supports pharmaceutical and life sciences teams with real-world data intelligence, strategic commercial insight and evidence generation.

GLOBAL MARKET FOOTPRINT

APAC-focused with evidence and data partnerships spanning:

China • Australia • Japan • South Korea • Taiwan • New Zealand

Additional support across the UK, EU, US, and other global markets on an ad hoc basis.

CAPABILITIES

Sourcing & Integrating
Real-World Data Globally

Advancing Analytical
Solutions

Delivering Strategic
Data Insights & Advisory

Building Powerful
Data Collaborations

Claims • EMR • Registry • GP • Lab • Genomics • Linked Data

team@aurumetrics.com

www.aurumetrics.com



AURUMETRICS